Entrada Therapeutics announced May 7 ↗ positive Phase 1/2 topline results from Cohort 1 of the ELEVATE-44-201 study of ENTR-601-44, the first-in-class Endosomal Escape Vehicle (EEV) peptide-PMO conjugate platform tested in Duchenne muscular dystrophy. At the 6 mg/kg dose, patients showed a 2.36% mean dystrophin increase from a 4.00% baseline, a statistically significant Time-to-Rise velocity improvement, and clean safety. This is the first DMD readout for Entrada's EEV platform and the first peptide-conjugate DMD clinical readout of 2026.
The biology context. Duchenne muscular dystrophy is an X-linked recessive genetic disorder caused by mutations in the dystrophin gene, the largest gene in the human genome. Patients lose ambulation in childhood, typically require ventilator support by adolescence, and die in early adulthood from cardiomyopathy or respiratory failure. The dystrophin gene encodes a structural protein that anchors the muscle fiber cytoskeleton to the extracellular matrix; its absence causes progressive muscle degeneration. Existing approved DMD drugs include exon-skipping antisense oligonucleotides (Sarepta's eteplirsen, golodirsen, casimersen, vyondys), which produce small-but-real dystrophin increases by causing the cell to skip mutated exons during mRNA splicing. The 2.36% mean dystrophin increase that ENTR-601-44 produced is in a similar range to the approved exon-skipping drugs.
The platform architecture. EEV stands for Endosomal Escape Vehicle. The peptide component is a cell-penetrating peptide designed to cross cellular membranes and escape from endosomes once internalized. The PMO (phosphorodiamidate morpholino oligomer) component is the antisense payload that performs the exon-skipping function. The conjugate is meant to solve the long-standing delivery problem in DMD: PMO drugs alone reach muscle tissue inefficiently, requiring high IV doses (up to 30 mg/kg weekly) to produce small dystrophin increases. The EEV peptide-PMO conjugate aims to deliver the PMO into muscle cells more efficiently, permitting lower doses with comparable or better dystrophin output.
The data. The 2.36% mean dystrophin increase from a 4.00% baseline is the headline efficacy number. Time-to-Rise (the time it takes a child with DMD to stand up from the floor, a standard pediatric DMD functional measure) showed statistically significant velocity improvement, meaning patients on ENTR-601-44 stood up faster than they did at baseline. Safety at the 6 mg/kg dose was clean. The trial design was Phase 1/2 dose-escalation, with Cohort 1 being the lowest evaluated dose; higher cohorts will read out subsequent quarters. The 6 mg/kg dose is well below the 30 mg/kg approved dose for the existing PMO drugs, reflecting the EEV platform's delivery efficiency.
How this fits the peptide-conjugate-architecture meta-pattern. The news section has tracked four peptide-conjugate-architecture papers in the past two weeks: the DiMarchi peptide-PPAR conjugate ↗ (May 1) for obesity, the BCL6-PROTAC LNP ↗ (May 4) for DLBCL, the NTyP-100 nanocarrier for ALI ↗ (May 7), and now Entrada's EEV peptide-PMO for DMD. Five peptide-conjugate clinical or preclinical readouts in eleven days, across four therapeutic indications. The modality is producing real results across multiple disease areas simultaneously, and ENTR-601-44 is the first of these to show positive data in actual patients rather than mice or cells.
The competitive context. The DMD treatment landscape has been dominated by exon-skipping PMOs (Sarepta), gene therapy (Sarepta's Elevidys, Solid Biosciences), and steroid alternatives (Santhera's Agamree). The EEV platform competes most directly with the established PMO drugs by promising better delivery at lower doses, which would reduce the IV burden patients face. Whether the 6 mg/kg ENTR-601-44 dose produces durable dystrophin restoration over time, and whether higher cohort doses produce proportionally greater effect, are the questions the rest of ELEVATE-44-201 will address.
What this is not. Approval-supportive data. Phase 1/2 cohort 1 is early-stage, and the regulatory path for DMD therapeutics requires substantial efficacy data across multiple cohorts and longer follow-up. The 2.36% dystrophin increase is biologically meaningful and statistically significant, but DMD efficacy has historically required cumulative dystrophin exposure over years to translate into functional patient benefit. The Time-to-Rise improvement in cohort 1 is encouraging but the trial size is small, and individual-patient variance can drive readouts that look better or worse than steady-state would predict.
The platform read. Peptide-PMO conjugates sit at the intersection of two design spaces the platform's broader card corpus engages: cell-penetrating peptides (the EEV peptide component) and antisense oligonucleotides (the PMO payload). As more EEV-platform drugs advance, the platform's annotation layer for cell-penetrating peptides becomes more clinically anchored. The DMD indication specifically connects to the muscle effects ↗ target territory the platform already covers, though for a different mechanism (myostatin antagonism vs. dystrophin restoration).
What 2026-2027 reveals. Whether Entrada advances ENTR-601-44 to higher dose cohorts with proportionally greater dystrophin increases. Whether longer follow-up shows functional improvement at the patient level. Whether the EEV platform extends to other indications (the company has additional candidates in early development for myotonic dystrophy and other muscle diseases). And whether the peptide-PMO architecture displaces unconjugated PMO as the standard delivery format for antisense oligonucleotide therapeutics.